Company Overview and News

 
Rent.com.au shares ride higher on achieving steady growth in users

2017-08-15 proactiveinvestors.com.au
Rental property website Rent.com.au (ASX:RNT) is witnessing strong growth for its Renter Resume feature, exceeding 150,000 resumes in just under 10 months.

 
Rent.com.au gets ready to raise

2016-10-25 proactiveinvestors.com.au
Rent.com.au Ltd (ASX:RNT) has been granted a trading halt by the ASX, pending details of a capital raising.

 
Rent.com.au Ltd partners with Airbnb for renters to try out properties

2016-08-25 proactiveinvestors.com.au
Rent.com.au Ltd (ASX:RNT) has entered into a partnering agreement with Airbnb to encourage renters to ‘try before they buy’ and test drive a new neighbourhood, before signing a rental lease. Rent.com.au is a website dedicated to rental property and includes listings from both property agents and non‐agent private landlords. There are benefits to private landlords as well who can cover short term periods of vacancy by listing on Airbnb.

 
Rent.com.au Ltd appoints Greg Bader chief executive officer

2016-08-23 proactiveinvestors.com.au
Rent.com.au Ltd (ASX:RNT) has appointed the experienced Greg Bader as its new chief executive officer. Bader most recently was a member of iiNet’s executive team. The appointment is effective immediately and follows a period of Bader acting as interim chief executive officer. Rent.com.au is an Australian web portal focused on the rental property market.

 
Rent.com.au Ltd bags $5.46M in raising, record landlord listings

2016-06-15 proactiveinvestors.com.au
Rent.com.au Ltd (ASX:RNT) is preparing a brand awareness drive as it moves to full commercialisation of its web portal, following a $5.46 million capital raising last month. The raising brought high profile investors aboard including Bill Moss AO, former head of real estate at Macquarie Bank and Charles Tarbey, the chairman of Century 21 Australia. The offer was pitched at $0.15 per share. Rent.com.

 
Appendix 3Y x4

2016-05-11 asx.com.au

 
Appendix 3B

2016-05-10 asx.com.au

 
April 2016 Operating Update

2016-05-05 asx.com.au

 
 
 
Investor Presentation

2016-04-08 asx.com.au

 
Prospectus

2016-04-07 asx.com.au

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...